Rat and mouse models remain foundational to biomedical research because their genetics, physiology, reproductive efficiency, and well-characterized disease pathways enable reproducible investigation across oncology, immunology, neuroscience, metabolic disorders, cardiovascular disease, infectious disease, toxicology, and pharmacology. The rat and mouse model ecosystem includes inbred, outbred, congenic, transgenic, knockout, knock-in, conditional, humanized, germ-free, gnotobiotic, immunodeficient, and disease-specific strains used in discovery research, preclinical validation, safety assessment, and translational studies. Demand is shaped by the continued need to understand complex biological mechanisms, evaluate therapeutic candidates, and generate evidence required for regulatory submissions while aligning with the 3Rs principles of replacement, reduction, and refinement. Key adoption drivers include CRISPR genome editing, advanced phenotyping, microbiome-controlled models, patient-derived xenograft research, human immune system reconstitution, and increasing use of digital monitoring to reduce stress and improve data quality. At the same time, the landscape is increasingly influenced by ethics review, reproducibility expectations, animal welfare standards, pathogen surveillance, supply-chain resilience, and the integration of non-animal methods where scientifically appropriate. As biomedical pipelines become more targeted and data-intensive, rat and mouse models are evolving from standardized research tools into precision biological platforms that connect genomics, environment, phenotype, and therapeutic response.

Transformative Shifts in the Rat & Mouse Model Landscape

The rat and mouse model landscape is undergoing a structural shift from conventional strain-based research toward precision, human-relevant, and highly controlled experimental systems. CRISPR-based genome editing has accelerated the creation of targeted genetic models, enabling faster development of knockouts, knock-ins, conditional alleles, and models carrying clinically relevant variants. Humanized mouse models are expanding the ability to study immune-oncology, infectious diseases, inflammation, transplantation, and biologics, while rats are gaining renewed importance in neuroscience, cardiovascular research, behavioral studies, toxicology, and surgical models because of their size and physiological suitability. Research organizations are also placing greater emphasis on microbiome standardization, germ-free and gnotobiotic facilities, environmental controls, and genetic quality assurance to address reproducibility concerns documented across preclinical science. Digital vivarium systems, automated home-cage monitoring, telemetry, imaging, and non-invasive biomarkers are transforming endpoint collection by enabling longitudinal data capture and reducing animal handling. Regulatory and funding bodies increasingly expect transparent reporting, appropriate statistical design, consideration of sex as a biological variable, and welfare-focused protocols. These shifts are reshaping procurement and study design decisions, with greater preference for validated models, defined health status, robust metadata, and integrated phenotyping services that support translational relevance.

Cumulative Impact of Artificial Intelligence on Rat & Mouse Models

Artificial intelligence is increasingly influencing the rat and mouse model ecosystem by improving study design, animal welfare monitoring, image analysis, phenotyping, colony management, and translational interpretation. Machine learning tools can analyze behavioral videos, gait patterns, sleep cycles, tumor growth images, histopathology slides, and physiological telemetry to detect subtle phenotypes that may be missed by manual observation. AI-supported experimental design can improve statistical power calculations, reduce unnecessary animal use, and help identify confounding variables such as cage effects, sex differences, microbiome variation, and circadian timing. In vivarium operations, predictive analytics supports breeding optimization, genotype planning, health surveillance, and resource allocation, helping reduce surplus animals and improve colony efficiency. In drug discovery and safety research, AI enables integration of omics data, imaging, pathology, and pharmacodynamic readouts to strengthen cross-species translation and identify signals earlier in the preclinical process. However, AI adoption also raises critical requirements for validated algorithms, explainable outputs, standardized data annotation, bias control, and compliance with animal research governance. The cumulative impact is not the replacement of rat and mouse models in the near term, but the refinement of their use through better data extraction, fewer experimental redundancies, improved welfare, and stronger reproducibility.

Key Regional Insights Across Global Rat & Mouse Model Research

In Asia-Pacific, growth in rat and mouse model research is supported by expanding biomedical infrastructure, national biotechnology programs, increasing translational research activity, and strong academic investment across China, India, Japan, South Korea, Australia, and ASEAN economies. China has become a major hub for genome editing, oncology models, humanized models, and preclinical drug development, while Japan and South Korea emphasize high-quality disease models, regenerative medicine, neuroscience, and biologics research. India is strengthening its contract research, toxicology, vaccine, and pharmacology capabilities, supported by a large scientific workforce and growing regulatory alignment. Australia contributes high standards in animal ethics, immunology, infectious disease, and translational medicine. North America remains one of the most advanced regions for rat and mouse model innovation, driven by extensive biomedical funding, mature vivarium infrastructure, strong regulatory frameworks, and deep expertise in genetically engineered, immunodeficient, and humanized rodent models. The United States is especially influential in cancer biology, neurodegeneration, rare disease, infectious disease, and safety pharmacology, while Canada is recognized for academic research networks, stem cell science, and ethical oversight. Latin America is developing capabilities in pharmacology, infectious disease, metabolic disorders, and toxicology, with Brazil and Mexico serving as important research centers, although infrastructure variability and funding cycles influence adoption. Europe is characterized by rigorous animal welfare regulation, strong implementation of the 3Rs, and advanced research across immunology, neuroscience, oncology, and toxicology, with major contributions from Germany, France, the United Kingdom, Italy, Spain, and other European research economies. The Middle East is investing in biomedical research capacity, genomics, and life science infrastructure, particularly in Gulf economies, while Africa is gradually expanding biomedical and infectious disease research capabilities, with opportunities linked to regional health priorities, training, ethical governance, and international research collaboration.

Key Group Insights Shaping Rat & Mouse Model Adoption

ASEAN is increasingly relevant to rat and mouse model research through expanding biomedical universities, vaccine research, infectious disease programs, and preclinical service capacity in countries with growing life science investment, supported by regional interest in tropical disease, metabolic disorders, and pharmaceutical development. The GCC is strengthening its role through national health research strategies, genomics initiatives, academic medical centers, and investment in laboratory infrastructure, with rat and mouse models supporting diabetes, cardiovascular disease, oncology, and precision medicine studies aligned with regional disease burdens. The European Union provides one of the most structured governance environments for animal research, with harmonized animal welfare legislation, mandatory ethical review, and strong 3Rs implementation that influence study design, reporting, and model selection across member states. BRICS countries represent a diverse and influential grouping for rat and mouse model activity, combining China's large-scale model generation and preclinical research capacity, India's expanding pharmacology and toxicology base, Brazil's infectious disease and metabolic research strengths, Russia's biomedical science legacy, and South Africa's role in regional health research. G7 countries continue to shape global best practices through advanced biomedical funding systems, stringent regulatory expectations, sophisticated disease model development, and strong publication output in translational science. NATO member countries, particularly those with established life science and defense-health research programs, use rat and mouse models in areas such as toxicology, biodefense, infectious disease, trauma, neuroscience, and medical countermeasure development. Across these groups, the defining themes are quality assurance, ethical compliance, genetically defined models, interoperable data, and increasing integration of digital and computational tools.

Key Country Insights for Rat & Mouse Model Research

The United States leads rat and mouse model innovation through extensive biomedical research infrastructure, strong use of genetically engineered models, and advanced applications in oncology, immunology, neuroscience, rare diseases, and toxicology. Canada contributes through high-quality academic research, stem cell biology, neurobiology, infectious disease studies, and robust ethics oversight. Mexico is expanding biomedical and pharmacology research capacity, with rodent models supporting toxicology, metabolic disease, and infectious disease studies. Brazil is a major Latin American contributor, using rat and mouse models in immunology, parasitology, vaccine research, metabolic disorders, and pharmacological evaluation. The United Kingdom is recognized for strong animal welfare governance, neuroscience, cancer research, genetics, and preclinical translational methods, while Germany has deep capabilities in molecular biology, immunology, cardiovascular research, toxicology, and advanced phenotyping. France supports broad rodent model use across oncology, infectious disease, neuroscience, and immunology, aided by major public research institutions and strict ethical review. Russia maintains expertise in biomedical science, pharmacology, physiology, and experimental medicine, although international collaboration dynamics and procurement conditions can affect research flow. Italy and Spain are active in oncology, neuroscience, inflammation, metabolic disease, and pharmacology, with European standards shaping animal use and reporting. China is one of the most dynamic countries for genome-edited, humanized, immunodeficient, and disease-specific mouse and rat models, supported by major investment in biotechnology and translational medicine. India is strengthening its position in toxicology, pharmacology, vaccine research, and disease modeling, driven by its expanding pharmaceutical and academic ecosystem. Japan has long-standing strengths in genetics, aging, neuroscience, immunology, regenerative medicine, and high-quality model development. Australia is prominent in immunology, infectious disease, cancer, and ethical animal research frameworks, while South Korea is advancing rapidly in genome editing, oncology, neuroscience, regenerative medicine, and preclinical research infrastructure. Collectively, these countries illustrate how regulatory standards, funding priorities, disease burden, technical capabilities, and animal welfare expectations shape rat and mouse model utilization.

Actionable Recommendations for Rat & Mouse Model Industry Leaders

Industry leaders should prioritize scientifically justified model selection, ensuring that each rat or mouse model is aligned with the biological mechanism, therapeutic modality, endpoint requirements, and translational objective of the study. Organizations should strengthen reproducibility by implementing genetic authentication, pathogen monitoring, microbiome documentation, standardized housing conditions, sex-balanced study designs where appropriate, and transparent reporting aligned with accepted preclinical research guidelines. Investment in advanced model platforms, including CRISPR-engineered strains, humanized immune system models, patient-derived xenografts, gnotobiotic systems, and longitudinal phenotyping technologies, can improve data relevance while supporting more efficient study execution. Leaders should integrate AI-enabled analytics, automated behavioral assessment, digital pathology, telemetry, and imaging to capture richer datasets and reduce subjective scoring. Animal welfare must remain central, with active adoption of the 3Rs, refined endpoints, non-invasive monitoring, environmental enrichment, and protocol-level review to minimize distress. Supply-chain resilience should be improved through diversified sourcing, cryopreservation strategies, contingency breeding plans, and clear health-status documentation. Finally, decision-makers should build cross-functional teams that connect veterinarians, geneticists, bioinformaticians, pharmacologists, statisticians, and regulatory specialists to improve experimental validity and accelerate translation from preclinical findings to clinical development.

Research Methodology for Rat & Mouse Model Analysis

This executive summary is developed through a structured secondary research approach that prioritizes verified, publicly available, and scientifically credible information. The methodology includes review of peer-reviewed literature, regulatory guidance, animal welfare frameworks, preclinical research reporting standards, biomedical research publications, government and institutional resources, and scientific consensus documents related to rat and mouse model development and use. The analysis considers major model categories, including inbred and outbred strains, genetically engineered models, immunodeficient models, humanized models, disease-specific models, germ-free and gnotobiotic systems, and toxicology models. Regional, group, and country insights are synthesized from observable biomedical research activity, regulatory environments, scientific infrastructure, funding priorities, ethical governance, and life science ecosystem maturity. The research approach avoids unsupported numerical claims, market sizing, market share statements, and forecasting. Emphasis is placed on validated trends such as genome editing adoption, 3Rs implementation, reproducibility requirements, digital phenotyping, AI-enabled analysis, and translational model refinement. Findings are triangulated across multiple categories of evidence to ensure relevance, consistency, and practical value for stakeholders involved in biomedical research, preclinical development, laboratory animal science, and translational medicine.

Conclusion

Rat and mouse models continue to play a critical role in biomedical discovery and preclinical development, while the way they are designed, managed, analyzed, and governed is changing rapidly. The sector is moving toward more precise genetic engineering, improved human relevance, better environmental and microbiome control, stronger ethical oversight, and richer digital phenotyping. Artificial intelligence is reinforcing this evolution by enabling more objective data interpretation, optimized breeding, improved welfare surveillance, and more efficient experimental design. Regional strengths vary, with North America and Europe emphasizing advanced infrastructure and governance, Asia-Pacific accelerating model generation and translational research, Latin America building capacity around regional disease priorities, and the Middle East and Africa expanding biomedical capabilities through targeted investment and collaboration. For industry leaders, success depends on combining high-quality models with rigorous study design, transparent reporting, animal welfare excellence, and data-driven decision-making. As non-animal methods, organoids, organ-on-chip systems, and computational models advance, rat and mouse models will increasingly be used in integrated evidence frameworks rather than in isolation. The future of the rat and mouse model landscape will be defined by scientific validity, ethical responsibility, reproducibility, and the ability to generate translational insights that support safer and more effective therapies.

Product Code: MRR-3A2E844FF329

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Rat & Mouse Model Market, by Species

7.1. Introduction
7.2. Rat Models
- 7.2.1. Outbred Rat Models
- 7.2.2. Inbred Rat Models
- 7.2.3. Genetically Engineered Rat Models
- 7.2.4. Immunodeficient Rat Models
7.3. Mouse Models
- 7.3.1. Outbred Mouse Models
- 7.3.2. Inbred Mouse Models
- 7.3.3. Genetically Engineered Mouse Models
  - 7.3.3.1. Knockout Mouse Models
  - 7.3.3.2. Transgenic Mouse Models
  - 7.3.3.3. Humanized Mouse Models
- 7.3.4. Immunodeficient Mouse Models
  - 7.3.4.1. Nude Mouse Models
  - 7.3.4.2. SCID Mouse Models
  - 7.3.4.3. NOG/NSG Mouse Models

8. Rat & Mouse Model Market, by Model Type

8.1. Introduction
8.2. Inbred Models
8.3. Outbred Models
8.4. Genetically Engineered Models
- 8.4.1. Knockout Models
  - 8.4.1.1. Constitutive Knockout Models
  - 8.4.1.2. Conditional Knockout Models
  - 8.4.1.3. Inducible Knockout Models
- 8.4.2. Transgenic Models
- 8.4.3. Humanized Models
- 8.4.4. Knock-in Models
8.5. Xenograft Models
- 8.5.1. Cell Line-Derived Xenograft Models
- 8.5.2. Patient-Derived Xenograft Models
8.6. Syngeneic Models
8.7. Chemically Induced Models
8.8. Diet-Induced Models
8.9. Surgically Induced Models
8.10. Spontaneous Disease Models
8.11. Reporter Models

9. Rat & Mouse Model Market, by Service Type

9.1. Introduction
9.2. Standard Model Supply
- 9.2.1. Live Animals
- 9.2.2. Cryopreserved Embryos & Sperm
9.3. Custom Model Generation
- 9.3.1. Gene Editing Design & Construction
- 9.3.2. Embryology & Microinjection Services
- 9.3.3. Validation & Quality Control
9.4. Breeding & Colony Management
- 9.4.1. Breeding Strategy Design
- 9.4.2. Colony Expansion & Maintenance
- 9.4.3. Health Monitoring
9.5. Cryopreservation & Recovery
- 9.5.1. Sperm Cryopreservation
- 9.5.2. Embryo Cryopreservation
- 9.5.3. Resuscitation Services
9.6. Rederivation & Health Status Improvement
9.7. Phenotyping & Behavior Testing
- 9.7.1. Physiological Phenotyping
- 9.7.2. Behavioral & Cognitive Testing
9.8. In Vivo Study Services
- 9.8.1. Efficacy Studies
- 9.8.2. Disease Induction & Monitoring
- 9.8.3. Surgical Modeling
9.9. Consulting & Regulatory Support

10. Rat & Mouse Model Market, by Application

10.1. Introduction
10.2. Drug Discovery & Screening
- 10.2.1. Target Identification & Validation
- 10.2.2. High-Throughput Screening
- 10.2.3. Lead Optimization
10.3. Preclinical Efficacy Studies
- 10.3.1. Dose-Response Studies
- 10.3.2. Combination Therapy Studies
10.4. Pharmacokinetics & Pharmacodynamics
- 10.4.1. Absorption, Distribution, Metabolism & Excretion
- 10.4.2. Exposure-Response Modeling
10.5. Safety & Toxicology Testing
- 10.5.1. Acute Toxicity
- 10.5.2. Chronic Toxicity
- 10.5.3. Carcinogenicity
- 10.5.4. Reproductive & Developmental Toxicity
10.6. Disease Mechanism & Pathophysiology Research
10.7. Biomarker Discovery & Validation
10.8. Translational & Biomimetic Studies
10.9. Education & Training

11. Rat & Mouse Model Market, by End User

11.1. Introduction
11.2. Pharmaceutical Companies
- 11.2.1. Top-Tier & Multinational Pharma
- 11.2.2. Mid-Size & Specialty Pharma
11.3. Biotechnology Companies
- 11.3.1. Established Biotech Firms
- 11.3.2. Emerging & Virtual Biotech
11.4. Contract Research Organizations
- 11.4.1. Global CROs
- 11.4.2. Niche Preclinical CROs
11.5. Academic & Research Institutes
- 11.5.1. Universities
- 11.5.2. Independent Research Institutes
11.6. Government & Public Sector Laboratories
11.7. Nonprofit & Foundations
11.8. Industry Consortia & Partnerships

12. Rat & Mouse Model Market, by Region

12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa

13. Rat & Mouse Model Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Rat & Mouse Model Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
- 15.3.1. Concentration Ratio (CR)
- 15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Biocytogen Pharmaceuticals Co., Ltd.
16.2. Champions Oncology, Inc.
16.3. Charles River Laboratories International, Inc.
16.4. Crown Bioscience International, Inc.
16.5. Cyagen Biosciences, Inc.
16.6. Envigo RMS, LLC
16.7. GemPharmatech Co., Ltd.
16.8. genOway S.A.
16.9. Harbour BioMed
16.10. Hera BioLabs, Inc.
16.11. inGenious Targeting Laboratory, Inc.
16.12. Janvier Labs SA
16.13. Oncodesign Precision Medicine
16.14. Oriental BioService Co., Ltd.
16.15. Ozgene Pty Ltd.
16.16. PerkinElmer, Inc.
16.17. Pharmatest Services Oy
16.18. PolyGene AG
16.19. Taconic Biosciences, Inc.
16.20. The Jackson Laboratory
16.21. TransCure bioServices
16.22. TransTech Pharma, Inc.
16.23. TransViragen, Inc.
16.24. Vivo Bio Tech Ltd.

Product Code: MRR-3A2E844FF329

LIST OF FIGURES

FIGURE 1. GLOBAL RAT & MOUSE MODEL MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RAT & MOUSE MODEL MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RAT & MOUSE MODEL MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RAT & MOUSE MODEL MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RAT & MOUSE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RAT & MOUSE MODEL MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL RAT & MOUSE MODEL MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

TABLE 1. GLOBAL RAT & MOUSE MODEL MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RAT & MOUSE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL OUTBRED RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL OUTBRED RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL OUTBRED RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INBRED RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INBRED RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL INBRED RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GENETICALLY ENGINEERED RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GENETICALLY ENGINEERED RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GENETICALLY ENGINEERED RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNODEFICIENT RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNODEFICIENT RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNODEFICIENT RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL OUTBRED MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL OUTBRED MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL OUTBRED MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INBRED MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL INBRED MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INBRED MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GENETICALLY ENGINEERED MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GENETICALLY ENGINEERED MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GENETICALLY ENGINEERED MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL KNOCKOUT MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL KNOCKOUT MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL KNOCKOUT MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL TRANSGENIC MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL TRANSGENIC MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL TRANSGENIC MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HUMANIZED MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HUMANIZED MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL HUMANIZED MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IMMUNODEFICIENT MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IMMUNODEFICIENT MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNODEFICIENT MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NUDE MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NUDE MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NUDE MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SCID MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SCID MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL SCID MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NOG/NSG MOUSE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NOG/NSG MOUSE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NOG/NSG MOUSE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL INBRED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL INBRED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL INBRED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL OUTBRED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL OUTBRED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL OUTBRED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GENETICALLY ENGINEERED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GENETICALLY ENGINEERED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GENETICALLY ENGINEERED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL KNOCKOUT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL KNOCKOUT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL KNOCKOUT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CONSTITUTIVE KNOCKOUT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CONSTITUTIVE KNOCKOUT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CONSTITUTIVE KNOCKOUT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CONDITIONAL KNOCKOUT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CONDITIONAL KNOCKOUT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CONDITIONAL KNOCKOUT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INDUCIBLE KNOCKOUT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL INDUCIBLE KNOCKOUT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL INDUCIBLE KNOCKOUT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL TRANSGENIC MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL TRANSGENIC MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL TRANSGENIC MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL HUMANIZED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL HUMANIZED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL HUMANIZED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL KNOCK-IN MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL KNOCK-IN MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL KNOCK-IN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL XENOGRAFT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL XENOGRAFT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL XENOGRAFT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CELL LINE-DERIVED XENOGRAFT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CELL LINE-DERIVED XENOGRAFT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CELL LINE-DERIVED XENOGRAFT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL PATIENT-DERIVED XENOGRAFT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PATIENT-DERIVED XENOGRAFT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL PATIENT-DERIVED XENOGRAFT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL SYNGENEIC MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL SYNGENEIC MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL SYNGENEIC MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CHEMICALLY INDUCED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CHEMICALLY INDUCED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CHEMICALLY INDUCED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL DIET-INDUCED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL DIET-INDUCED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL DIET-INDUCED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL SURGICALLY INDUCED MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL SURGICALLY INDUCED MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL SURGICALLY INDUCED MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL SPONTANEOUS DISEASE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL SPONTANEOUS DISEASE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL SPONTANEOUS DISEASE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL REPORTER MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL REPORTER MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL REPORTER MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL STANDARD MODEL SUPPLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL STANDARD MODEL SUPPLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL STANDARD MODEL SUPPLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL LIVE ANIMALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL LIVE ANIMALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL LIVE ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL CRYOPRESERVED EMBRYOS & SPERM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CRYOPRESERVED EMBRYOS & SPERM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CRYOPRESERVED EMBRYOS & SPERM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL CUSTOM MODEL GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL CUSTOM MODEL GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL CUSTOM MODEL GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL GENE EDITING DESIGN & CONSTRUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL GENE EDITING DESIGN & CONSTRUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL GENE EDITING DESIGN & CONSTRUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL EMBRYOLOGY & MICROINJECTION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL EMBRYOLOGY & MICROINJECTION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL EMBRYOLOGY & MICROINJECTION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL VALIDATION & QUALITY CONTROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL VALIDATION & QUALITY CONTROL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL VALIDATION & QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL BREEDING & COLONY MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL BREEDING & COLONY MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL BREEDING & COLONY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL BREEDING STRATEGY DESIGN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL BREEDING STRATEGY DESIGN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL BREEDING STRATEGY DESIGN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL COLONY EXPANSION & MAINTENANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL COLONY EXPANSION & MAINTENANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL COLONY EXPANSION & MAINTENANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL HEALTH MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL HEALTH MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL HEALTH MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL CRYOPRESERVATION & RECOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL CRYOPRESERVATION & RECOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL CRYOPRESERVATION & RECOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL SPERM CRYOPRESERVATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL SPERM CRYOPRESERVATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL SPERM CRYOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL EMBRYO CRYOPRESERVATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL EMBRYO CRYOPRESERVATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL EMBRYO CRYOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL RESUSCITATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL RESUSCITATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL RESUSCITATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL REDERIVATION & HEALTH STATUS IMPROVEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL REDERIVATION & HEALTH STATUS IMPROVEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL REDERIVATION & HEALTH STATUS IMPROVEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL PHENOTYPING & BEHAVIOR TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL PHENOTYPING & BEHAVIOR TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL PHENOTYPING & BEHAVIOR TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL PHYSIOLOGICAL PHENOTYPING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL PHYSIOLOGICAL PHENOTYPING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL PHYSIOLOGICAL PHENOTYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL BEHAVIORAL & COGNITIVE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL BEHAVIORAL & COGNITIVE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL BEHAVIORAL & COGNITIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL IN VIVO STUDY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 169. GLOBAL IN VIVO STUDY SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL IN VIVO STUDY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL EFFICACY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 172. GLOBAL EFFICACY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL EFFICACY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL DISEASE INDUCTION & MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 175. GLOBAL DISEASE INDUCTION & MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 176. GLOBAL DISEASE INDUCTION & MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL SURGICAL MODELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 178. GLOBAL SURGICAL MODELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL SURGICAL MODELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL CONSULTING & REGULATORY SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 181. GLOBAL CONSULTING & REGULATORY SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL CONSULTING & REGULATORY SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 184. GLOBAL DRUG DISCOVERY & SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL DRUG DISCOVERY & SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL DRUG DISCOVERY & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 188. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 189. GLOBAL TARGET IDENTIFICATION & VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. GLOBAL HIGH-THROUGHPUT SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL HIGH-THROUGHPUT SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. GLOBAL HIGH-THROUGHPUT SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 194. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 195. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. GLOBAL PRECLINICAL EFFICACY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 197. GLOBAL PRECLINICAL EFFICACY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 198. GLOBAL PRECLINICAL EFFICACY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. GLOBAL DOSE-RESPONSE STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 200. GLOBAL DOSE-RESPONSE STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 201. GLOBAL DOSE-RESPONSE STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. GLOBAL COMBINATION THERAPY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 203. GLOBAL COMBINATION THERAPY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 204. GLOBAL COMBINATION THERAPY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. GLOBAL PHARMACOKINETICS & PHARMACODYNAMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL PHARMACOKINETICS & PHARMACODYNAMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 207. GLOBAL PHARMACOKINETICS & PHARMACODYNAMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. GLOBAL ABSORPTION, DISTRIBUTION, METABOLISM & EXCRETION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 209. GLOBAL ABSORPTION, DISTRIBUTION, METABOLISM & EXCRETION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 210. GLOBAL ABSORPTION, DISTRIBUTION, METABOLISM & EXCRETION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. GLOBAL EXPOSURE-RESPONSE MODELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 212. GLOBAL EXPOSURE-RESPONSE MODELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 213. GLOBAL EXPOSURE-RESPONSE MODELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. GLOBAL SAFETY & TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 215. GLOBAL SAFETY & TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 216. GLOBAL SAFETY & TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. GLOBAL ACUTE TOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 218. GLOBAL ACUTE TOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 219. GLOBAL ACUTE TOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. GLOBAL CHRONIC TOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 221. GLOBAL CHRONIC TOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 222. GLOBAL CHRONIC TOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. GLOBAL CARCINOGENICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 224. GLOBAL CARCINOGENICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 225. GLOBAL CARCINOGENICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. GLOBAL REPRODUCTIVE & DEVELOPMENTAL TOXICITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 227. GLOBAL REPRODUCTIVE & DEVELOPMENTAL TOXICITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 228. GLOBAL REPRODUCTIVE & DEVELOPMENTAL TOXICITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. GLOBAL DISEASE MECHANISM & PATHOPHYSIOLOGY RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 230. GLOBAL DISEASE MECHANISM & PATHOPHYSIOLOGY RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 231. GLOBAL DISEASE MECHANISM & PATHOPHYSIOLOGY RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. GLOBAL BIOMARKER DISCOVERY & VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 233. GLOBAL BIOMARKER DISCOVERY & VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 234. GLOBAL BIOMARKER DISCOVERY & VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 235. GLOBAL TRANSLATIONAL & BIOMIMETIC STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 236. GLOBAL TRANSLATIONAL & BIOMIMETIC STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 237. GLOBAL TRANSLATIONAL & BIOMIMETIC STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 238. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 239. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 240. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 243. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 244. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 245. GLOBAL TOP-TIER & MULTINATIONAL PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 246. GLOBAL TOP-TIER & MULTINATIONAL PHARMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 247. GLOBAL TOP-TIER & MULTINATIONAL PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 248. GLOBAL MID-SIZE & SPECIALTY PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 249. GLOBAL MID-SIZE & SPECIALTY PHARMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 250. GLOBAL MID-SIZE & SPECIALTY PHARMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 251. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 252. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 253. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 254. GLOBAL ESTABLISHED BIOTECH FIRMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 255. GLOBAL ESTABLISHED BIOTECH FIRMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 256. GLOBAL ESTABLISHED BIOTECH FIRMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 257. GLOBAL EMERGING & VIRTUAL BIOTECH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 258. GLOBAL EMERGING & VIRTUAL BIOTECH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 259. GLOBAL EMERGING & VIRTUAL BIOTECH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 260. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 261. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 262. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 263. GLOBAL GLOBAL CROS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 264. GLOBAL GLOBAL CROS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 265. GLOBAL GLOBAL CROS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 266. GLOBAL NICHE PRECLINICAL CROS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 267. GLOBAL NICHE PRECLINICAL CROS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 268. GLOBAL NICHE PRECLINICAL CROS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 269. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 270. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 271. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 272. GLOBAL UNIVERSITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 273. GLOBAL UNIVERSITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 274. GLOBAL UNIVERSITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 275. GLOBAL INDEPENDENT RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 276. GLOBAL INDEPENDENT RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 277. GLOBAL INDEPENDENT RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 278. GLOBAL GOVERNMENT & PUBLIC SECTOR LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 279. GLOBAL GOVERNMENT & PUBLIC SECTOR LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 280. GLOBAL GOVERNMENT & PUBLIC SECTOR LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 281. GLOBAL NONPROFIT & FOUNDATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 282. GLOBAL NONPROFIT & FOUNDATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 283. GLOBAL NONPROFIT & FOUNDATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 284. GLOBAL INDUSTRY CONSORTIA & PARTNERSHIPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 285. GLOBAL INDUSTRY CONSORTIA & PARTNERSHIPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 286. GLOBAL INDUSTRY CONSORTIA & PARTNERSHIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 287. GLOBAL RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 288. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 289. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 290. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY RAT MODELS, 2018-2032 (USD MILLION)
TABLE 291. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY MOUSE MODELS, 2018-2032 (USD MILLION)
TABLE 292. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODELS, 2018-2032 (USD MILLION)
TABLE 293. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT MOUSE MODELS, 2018-2032 (USD MILLION)
TABLE 294. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
TABLE 295. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
TABLE 296. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MODELS, 2018-2032 (USD MILLION)
TABLE 297. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY XENOGRAFT MODELS, 2018-2032 (USD MILLION)
TABLE 298. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 299. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY STANDARD MODEL SUPPLY, 2018-2032 (USD MILLION)
TABLE 300. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY CUSTOM MODEL GENERATION, 2018-2032 (USD MILLION)
TABLE 301. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY BREEDING & COLONY MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 302. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVATION & RECOVERY, 2018-2032 (USD MILLION)
TABLE 303. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY PHENOTYPING & BEHAVIOR TESTING, 2018-2032 (USD MILLION)
TABLE 304. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY IN VIVO STUDY SERVICES, 2018-2032 (USD MILLION)
TABLE 305. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 306. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY DRUG DISCOVERY & SCREENING, 2018-2032 (USD MILLION)
TABLE 307. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY PRECLINICAL EFFICACY STUDIES, 2018-2032 (USD MILLION)
TABLE 308. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY PHARMACOKINETICS & PHARMACODYNAMICS, 2018-2032 (USD MILLION)
TABLE 309. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY SAFETY & TOXICOLOGY TESTING, 2018-2032 (USD MILLION)
TABLE 310. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 311. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 312. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 313. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
TABLE 314. ASIA-PACIFIC RAT & MOUSE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 315. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 316. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 317. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY RAT MODELS, 2018-2032 (USD MILLION)
TABLE 318. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY MOUSE MODELS, 2018-2032 (USD MILLION)
TABLE 319. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODELS, 2018-2032 (USD MILLION)
TABLE 320. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT MOUSE MODELS, 2018-2032 (USD MILLION)
TABLE 321. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
TABLE 322. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
TABLE 323. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MODELS, 2018-2032 (USD MILLION)
TABLE 324. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY XENOGRAFT MODELS, 2018-2032 (USD MILLION)
TABLE 325. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 326. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY STANDARD MODEL SUPPLY, 2018-2032 (USD MILLION)
TABLE 327. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY CUSTOM MODEL GENERATION, 2018-2032 (USD MILLION)
TABLE 328. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY BREEDING & COLONY MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 329. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY CRYOPRESERVATION & RECOVERY, 2018-2032 (USD MILLION)
TABLE 330. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY PHENOTYPING & BEHAVIOR TESTING, 2018-2032 (USD MILLION)
TABLE 331. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY IN VIVO STUDY SERVICES, 2018-2032 (USD MILLION)
TABLE 332. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 333. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY DRUG DISCOVERY & SCREENING, 2018-2032 (USD MILLION)
TABLE 334. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY PRECLINICAL EFFICACY STUDIES, 2018-2032 (USD MILLION)
TABLE 335. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY PHARMACOKINETICS & PHARMACODYNAMICS, 2018-2032 (USD MILLION)
TABLE 336. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY SAFETY & TOXICOLOGY TESTING, 2018-2032 (USD MILLION)
TABLE 337. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 338. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 339. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 340. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
TABLE 341. NORTH AMERICA RAT & MOUSE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 342. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 343. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
TABLE 344. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY RAT MODELS, 2018-2032 (USD MILLION)
TABLE 345. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY MOUSE MODELS, 2018-2032 (USD MILLION)
TABLE 346. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODELS, 2018-2032 (USD MILLION)
TABLE 347. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY IMMUNODEFICIENT MOUSE MODELS, 2018-2032 (USD MILLION)
TABLE 348. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
TABLE 349. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
TABLE 350. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY KNOCKOUT MODELS, 2018-2032 (USD MILLION)
TABLE 351. LATIN AMERICA RAT & MOUSE MODEL MARKET SIZE, BY XEN

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION